The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

(2019) Koutaro Yokote et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps

(2019) Raul D. Santos et al.   ATHEROSCLEROSIS

Long-term Pemafibrate Treatment Was Well Tolerated in Patients with Dyslipidemia Including Those with Kidney Dysfunction

(2018) Koutaro Yokote et al.   ATHEROSCLEROSIS SUPPLEMENTS

Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα

(2018) Yuta Yamamoto et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial

(2018) Antonio J. Vallejo-Vaz et al.   CIRCULATION

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine

(2018) Kershaw V. Patel et al.   CIRCULATION

Tofogliflozin and Pemafibrate Combination Therapy Prevents Nonalcoholic Steatohepatitis (NASH) Development of Novel Metabolic Syndrome–Related NASH Model Mice

(2018) YUSUKE SASAKI et al.   DIABETES

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

(2018) Eiichi Araki et al.   DIABETES CARE

Molecular actions of PPARα in lipid metabolism and inflammation

(2018) Nadia Bougarne et al.   ENDOCRINE REVIEWS

Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction

(2018) Olubunmi O. Olubamwo et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver

(2018) Maka S. Hedrington et al.   Expert Opinion on Drug Metabolism & Toxicology

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice

(2018) Masami Sairyo et al.   Journal of Atherosclerosis and Thrombosis

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

(2018) Hidenori Arai et al.   Journal of Atherosclerosis and Thrombosis

Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States

(2018) Iliana Doycheva et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

(2018) Shizuya Yamashita et al.   Journal of Clinical Lipidology

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

(2018) Sonia S Anand et al.   LANCET

Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update

(2018) Marie-Eve Piché et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

(2018) Ikuro Matsuba et al.   Journal of Diabetes Investigation

Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism

(2018) Anusha Angajala et al.   Frontiers in Immunology

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks

(2018) Theingi Aung et al.   JAMA Cardiology

Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol

(2018) Gregory A. Nichols et al.   DIABETES OBESITY & METABOLISM

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

(2018) Masaya Araki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice

(2018) Chad N. Brocker et al.   JOURNAL OF LIPID RESEARCH

NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4

(2018) James E Bennett et al.   LANCET

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

(2018) Peter P. Toth et al.   Journal of the American Heart Association

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

(2018) Aruna D. Pradhan et al.   AMERICAN HEART JOURNAL

Low-Grade Inflammation in the Association Between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population

(2018) Signe E. J. Hansen et al.   CLINICAL CHEMISTRY

Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey

(2018) Wenjun Fan et al.   Journal of Clinical Lipidology

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals

(2017) Bo Kobberø Lauridsen et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

(2017) Leon A Adams et al.   GUT

Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment

(2017) Carlos I. Ponte-Negretti et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease

(2017) Amit V. Khera et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

(2017) Kenta Takei et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway

(2017) Toshinobu Maki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Angiopoietin-like 3 in lipoprotein metabolism

(2017) Sander Kersten   Nature Reviews Endocrinology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

(2017) Marc S Sabatine et al.   Lancet Diabetes & Endocrinology

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

(2017) Marshall B. Elam et al.   JAMA Cardiology

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

(2017) Marc P. Bonaca et al.   CIRCULATION

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

(2017) Yasushi Honda et al.   Scientific Reports

Non-HDL Cholesterol and TriglyceridesHighlights

(2016) Rishi Puri et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

(2016) Nathalie Hennuyer et al.   ATHEROSCLEROSIS

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

(2016) Shun Ishibashi et al.   ATHEROSCLEROSIS

FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues

(2016) Christian Schlein et al.   Cell Metabolism

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.  

Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease

(2016) A.-M. K. Jepsen et al.   CLINICAL CHEMISTRY

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

(2016) Marja-Riitta Taskinen et al.   Current Atherosclerosis Reports

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

(2016) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

(2016) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.   Circulation-Cardiovascular Quality and Outcomes

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal ObesitySignificance

(2015) Jan Borén et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population

(2015) A. Varbo et al.   CLINICAL CHEMISTRY

Acetyl-CoA and the regulation of metabolism: mechanisms and consequences

(2015) Lei Shi et al.   CURRENT OPINION IN CELL BIOLOGY

Metabolic roles of PGC-1α and its implications for type 2 diabetes

(2015) A. Besseiche et al.   DIABETES & METABOLISM

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015

(2015) Yehuda Handelsman et al.   Endocrine Practice

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

(2015) Tomas Jernberg et al.   EUROPEAN HEART JOURNAL

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver

(2015) Sana Raza-Iqbal et al.   Journal of Atherosclerosis and Thrombosis

Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins

(2015) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties

(2015) Alexei Kharitonenkov et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Triglycerides on the rise: should we swap seats on the seesaw?

(2014) Peter Libby   EUROPEAN HEART JOURNAL

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

(2013) Željko Reiner et al.   ATHEROSCLEROSIS

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

(2013) Jean-Charles Fruchart   Cardiovascular Diabetology

Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus

(2013) Frank M. Sacks et al.   CIRCULATION

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

(2013) et al.   EUROPEAN HEART JOURNAL

Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment

(2013) Anette Varbo et al.   PHARMACOLOGY & THERAPEUTICS

Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

(2012) J. C. Mychaleckyj et al.   DIABETES CARE

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion

(2012) Chunyu Zheng et al.   EUROPEAN HEART JOURNAL

Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006

(2012) Peter P. Tóth et al.   Journal of Clinical Lipidology

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

(2012) Anette Varbo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

PPARs at the crossroads of lipid signaling and inflammation

(2012) Walter Wahli et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Apolipoprotein A-V; a potent triglyceride reducer

(2011) Stefan K. Nilsson et al.   ATHEROSCLEROSIS

Triglycerides and Cardiovascular Disease

(2011) Michael Miller et al.   CIRCULATION

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

(2010) T. M. E. Davis et al.   DIABETOLOGIA

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

(2009) Ole Faergeman et al.   AMERICAN JOURNAL OF CARDIOLOGY

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

(2009) Jean-Charles Fruchart   ATHEROSCLEROSIS

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

(2008) Jean-Charles Fruchart et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

(2008) John J.P. Kastelein et al.   CIRCULATION

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine